1. Pink Sheet
  2. >>Product Reviews
  3. >>Approvals

Keeping Track: A Massive Week Of Agency Approvals

 
• By Michael Cipriano

The latest drug approval and development news from our US FDA Performance Tracker.

Here's your news in brief: Approvals galore was the theme of the week, with the US FDA approving at least nine product applications. The biggest regulatory development was clearance of the first indication based on a basket trial, Genentech Inc.'s supplemental approval of its kinase inhibitor Zelboraf (vemurafenib) for the treatment of patients with Erdheim-Chester Disease (ECD) with a BRAF V600 mutation.

Most notably in original approvals, the agency finally gave its blessing to Dynavax Technologies Corp

Read the full article – start your free trial today!

Join thousands of industry professionals who rely on Pink Sheet for daily insights

  • Start your 7-day free trial
  • Explore trusted news, analysis, and insights
  • Access comprehensive global coverage
  • Enjoy instant access – no credit card required
Start Free Trial

Already a subscriber?

More from Approvals

More from Product Reviews

FDA Adcomms Are Back: Four Cancer Drugs, COVID-19 Vaccine Formulations To Get Reviews

 
• By Sue Sutter and Bridget Silverman

The Oncologic Drugs Advisory Committee will meet for two days in mid-May, followed by a Vaccines and Related Biological Products Advisory Committee’s review of the 2025-2026 COVID-19 vaccine formulation.

Unlocking Opportunities: How To Engage With The EMA On Animal Testing Alternatives

 
• By Neena Brizmohun

The European Medicines Agency, like its counterpart in the US, is increasingly focusing on the use of alternatives to animal testing.

Opioid Safety: US FDA Hears Mixed Messages On Adding Posmarketing Studies To Labeling

 
• By Sue Sutter

Some advisory committee members said adding quantitative data on misuse, abuse, opioid use disorder and overdose to labeling would be helpful, but others worried the two epidemiological studies were not sufficiently generalizable to a broader population.